Research analysts at Jefferies Financial Group started coverage on shares of Commonwealth Bank of Australia (OTCMKTS:CSLLY) in a note issued to investors on Monday, The Fly reports. The firm set a “buy” rating on the stock.
CSLLY has been the subject of a number of other reports. ValuEngine lowered shares of Commonwealth Bank of Australia from a “hold” rating to a “sell” rating in a research note on Wednesday, October 2nd. Zacks Investment Research lowered shares of Commonwealth Bank of Australia from a “hold” rating to a “sell” rating in a research report on Monday, October 14th.
Shares of CSLLY opened at $86.10 on Monday. The stock has a market capitalization of $77.95 billion, a price-to-earnings ratio of 40.61 and a beta of 0.65. Commonwealth Bank of Australia has a 12-month low of $60.89 and a 12-month high of $86.89. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.53 and a quick ratio of 1.14. The company’s fifty day moving average is $81.44.
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders.
Featured Article: What are the Different Types of Leveraged Buyouts?
Receive News & Ratings for Commonwealth Bank of Australia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Commonwealth Bank of Australia and related companies with MarketBeat.com's FREE daily email newsletter.